Literature DB >> 30635453

Using backbone-cyclized Cys-rich polypeptides as molecular scaffolds to target protein-protein interactions.

Dipankar Chaudhuri1, Teshome Aboye1, Julio A Camarero2,3,4.   

Abstract

The use of disulfide-rich backbone-cyclized polypeptides, as molecular scaffolds to design a new generation of bioimaging tools and drugs that are potent and specific, and thus might have fewer side effects than traditional small-molecule drugs, is gaining increasing interest among the scientific and in the pharmaceutical industries. Highly constrained macrocyclic polypeptides are exceptionally more stable to chemical, thermal and biological degradation and show better biological activity when compared with their linear counterparts. Many of these relatively new scaffolds have been also found to be highly tolerant to sequence variability, aside from the conserved residues forming the disulfide bonds, able to cross cellular membranes and modulate intracellular protein-protein interactions both in vitro and in vivo These properties make them ideal tools for many biotechnological applications. The present study provides an overview of the new developments on the use of several disulfide-rich backbone-cyclized polypeptides, including cyclotides, θ-defensins and sunflower trypsin inhibitor peptides, in the development of novel bioimaging reagents and therapeutic leads.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  CCK; cyclic peptides; cyclotides; cystine knot; drug design; protein–protein interactions

Mesh:

Substances:

Year:  2019        PMID: 30635453      PMCID: PMC7080216          DOI: 10.1042/BCJ20180792

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  109 in total

1.  Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin.

Authors:  Wei Wang; Chandrika Mulakala; Sabrina C Ward; Grace Jung; Hai Luong; Duy Pham; Alan J Waring; Yiannis Kaznessis; Wuyuan Lu; Kenneth A Bradley; Robert I Lehrer
Journal:  J Biol Chem       Date:  2006-06-21       Impact factor: 5.157

Review 2.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

3.  Design of Potent and Selective Cathepsin G Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold.

Authors:  Joakim E Swedberg; Choi Yi Li; Simon J de Veer; Conan K Wang; David J Craik
Journal:  J Med Chem       Date:  2017-01-18       Impact factor: 7.446

4.  Alternative binding proteins get mature: rivalling antibodies.

Authors:  Harald Kolmar; Arne Skerra
Journal:  FEBS J       Date:  2008-04-24       Impact factor: 5.542

5.  Engineering potent mesotrypsin inhibitors based on the plant-derived cyclic peptide, sunflower trypsin inhibitor-1.

Authors:  Simon J de Veer; Choi Yi Li; Joakim E Swedberg; Christina I Schroeder; David J Craik
Journal:  Eur J Med Chem       Date:  2018-06-21       Impact factor: 6.514

6.  Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.

Authors:  T L Veveris-Lowe; M G Lawrence; R L Collard; L Bui; A C Herington; D L Nicol; J A Clements
Journal:  Endocr Relat Cancer       Date:  2005-09       Impact factor: 5.678

7.  Using the MCoTI-II Cyclotide Scaffold To Design a Stable Cyclic Peptide Antagonist of SET, a Protein Overexpressed in Human Cancer.

Authors:  Charlotte D'Souza; Sónia Troeira Henriques; Conan K Wang; Olivier Cheneval; Lai Yue Chan; Nilesh J Bokil; Matthew J Sweet; David J Craik
Journal:  Biochemistry       Date:  2016-01-06       Impact factor: 3.162

8.  Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1.

Authors:  Alexander M Cole; Teresa Hong; Lee Ming Boo; Tung Nguyen; Chengquan Zhao; Greg Bristol; Jerome A Zack; Alan J Waring; Otto O Yang; Robert I Lehrer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

9.  Alanine scanning mutagenesis of the prototypic cyclotide reveals a cluster of residues essential for bioactivity.

Authors:  Shane M Simonsen; Lillian Sando; K Johan Rosengren; Conan K Wang; Michelle L Colgrave; Norelle L Daly; David J Craik
Journal:  J Biol Chem       Date:  2008-02-07       Impact factor: 5.157

10.  Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration.

Authors:  Lai Yue Chan; David J Craik; Norelle L Daly
Journal:  Biosci Rep       Date:  2015-10-13       Impact factor: 3.840

View more
  7 in total

1.  Recombinant Expression of Cyclotides Using Expressed Protein Ligation.

Authors:  Maria Jose Campbell; Jingtan Su; Julio A Camarero
Journal:  Methods Mol Biol       Date:  2020

Review 2.  The Potential of the Cyclotide Scaffold for Drug Development.

Authors:  Julio A Camarero; Maria Jose Campbell
Journal:  Biomedicines       Date:  2019-04-19

Review 3.  Modulating Protein-Protein Interactions by Cyclic and Macrocyclic Peptides. Prominent Strategies and Examples.

Authors:  Rosario González-Muñiz; María Ángeles Bonache; María Jesús Pérez de Vega
Journal:  Molecules       Date:  2021-01-16       Impact factor: 4.411

Review 4.  Bowman-Birk Inhibitors: Insights into Family of Multifunctional Proteins and Peptides with Potential Therapeutical Applications.

Authors:  Agata Gitlin-Domagalska; Aleksandra Maciejewska; Dawid Dębowski
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-25

Review 5.  Using the Cyclotide Scaffold for Targeting Biomolecular Interactions in Drug Development.

Authors:  Binu Jacob; Alicia Vogelaar; Enrique Cadenas; Julio A Camarero
Journal:  Molecules       Date:  2022-09-29       Impact factor: 4.927

Review 6.  Plant derived cyclic peptides.

Authors:  Norelle L Daly; David T Wilson
Journal:  Biochem Soc Trans       Date:  2021-06-30       Impact factor: 5.407

7.  Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity.

Authors:  Rajasekaran Ganesan; Mansour A Dughbaj; Lisa Ramirez; Steven Beringer; Teshome L Aboye; Alexander Shekhtman; Paul M Beringer; Julio A Camarero
Journal:  Chemistry       Date:  2021-08-06       Impact factor: 5.020

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.